In January 2024, Better Therapeutics, Inc submitted a request to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its new prescription digital therapeutic (PDT) designed to treat metabolic...
In January 2024, Better Therapeutics, Inc submitted a request to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its new prescription digital therapeutic (PDT) designed to treat metabolic...
In January 2024, Better Therapeutics Inc. and Glooko Inc. announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
In January 2024, Better Therapeutics Inc. and Glooko Inc. announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
In July 2023, GoodRx announced the launch of a new app known as Medicine Cabinet. In the press release, the company described the novel app as “a comprehensive solution designed to help consumers seamlessly manage their medications. Medicine...
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Prescription digital therapeutics (PDTs) allow patients and prescribers to work collaboratively and to use ongoing technological advances to diagnose, treat, and manage various conditions effectively. Unfortunately, it appears that a lack of...
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Prescription digital therapeutics offer the potential to improve adherence and clinical outcomes while decreasing direct and indirect costs, addressing gaps in care, and enabling patients to take an active role in their care.
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
As the number of PDTs continues to enter the market, it is important that clinicians and patients are aware of the regulatory processes instituted by the FDA to ensure the efficacy and safety of PDTs, and knowledge about the meticulous and...
As the number of PDTs continues to enter the market, it is important that clinicians and patients are aware of the regulatory processes instituted by the FDA to ensure the efficacy and safety of PDTs, and knowledge about the meticulous and...
Otsuka's Coverage Expectations Survey results regarding payer perspectives on prescription digital therapeutics (PDT) coverage revealed that payers recognize the potential value of PDTs while highlighting the need for clarity in FDA...
Otsuka's Coverage Expectations Survey results regarding payer perspectives on prescription digital therapeutics (PDT) coverage revealed that payers recognize the potential value of PDTs while highlighting the need for clarity in FDA...
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
PDTs have the potential to provide an additional tool to foster a patient-centered approach to managing diabetes while also making the patient an active partner in their day-to-day care, which in turn can improve glycemic control and reduce...
PDTs have the potential to provide an additional tool to foster a patient-centered approach to managing diabetes while also making the patient an active partner in their day-to-day care, which in turn can improve glycemic control and reduce...
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
While the number of prescription digital therapeutics (PDTs) continues to expand as possible treatments or adjunctive treatments for the management and prevention of various medical conditions, the degree of knowledge about the availability...
While the number of prescription digital therapeutics (PDTs) continues to expand as possible treatments or adjunctive treatments for the management and prevention of various medical conditions, the degree of knowledge about the availability...
Yvette C Terrie, BS Pharm, RPh, consultant pharmacist
As the number of prescription digital therapeutics (PDTs) expands, health care providers and patients are still largely unaware of their availability and potential benefits, highlighting the need for increased awareness and education...
As the number of prescription digital therapeutics (PDTs) expands, health care providers and patients are still largely unaware of their availability and potential benefits, highlighting the need for increased awareness and education...
Ignoring the appropriate use of drugs is equally harmful when negotiating with PBMs, as it can and does result in the wrong drugs getting on a formulary with the obvious downstream effect on patient care, costs, and outcomes.
Ignoring the appropriate use of drugs is equally harmful when negotiating with PBMs, as it can and does result in the wrong drugs getting on a formulary with the obvious downstream effect on patient care, costs, and outcomes.
Jennifer L. Mathieu Senior Vice President, Professional and Government Affairs, AMCP
Learn about developments in federal legislation and regulations within the pharmacy landscape shaping the future of managed care in an interview with a session presenter from AMCP 2024.
Learn about developments in federal legislation and regulations within the pharmacy landscape shaping the future of managed care in an interview with a session presenter from AMCP 2024.
An analysis showed agents that target interleukins are significantly associated with reduced rates of asthma exacerbation for patients with severe disease.
An analysis showed agents that target interleukins are significantly associated with reduced rates of asthma exacerbation for patients with severe disease.
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
New Orleans—A retrospective analysis of a managed care claims database found that from 2007 to 2012, there was an increase in the proportion of patients who took rituximab to treat diffuse large B-cell lymphoma (DLBCL) in a hospital setting...
Featuring Tejaswi Kompala, MD, head of cardiometabolic clinical strategy, Teladoc
Featuring Tejaswi Kompala, MD, head o...
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Delve into the rising demand for anti-obesity medications, the complexities of obesity management, and the importance of personalized approaches in improving cardiometabolic health in this insightful interview.
Join us for the continuation of an engaging two-part series showcasing an expert dedicated to reducing emergency department visits through the integration of behavioral health practices. Dr Zaubler will share invaluable insights into...
Join us for the continuation of an engaging two-part series showcasing an expert dedicated to reducing emergency department visits through the integration of behavioral health practices. Dr Zaubler will share invaluable insights into...
Come join us for the first installment of a captivating two-part series featuring an expert committed to minimizing emergency department visits through the implementation of behavioral health integrations. Dr Zaubler will offer valuable...
Come join us for the first installment of a captivating two-part series featuring an expert committed to minimizing emergency department visits through the implementation of behavioral health integrations. Dr Zaubler will offer valuable...
Featuring Yash Prajapati, consultant at ZS Associates
Featuring Yash Prajapati, consultant ...
Join us in exploring the challenges and opportunities in the development, approval, and integration of digital therapeutic solutions with ZS Associates consultant Yash Prajapati.
Join us in exploring the challenges and opportunities in the development, approval, and integration of digital therapeutic solutions with ZS Associates consultant Yash Prajapati.
Featuring Mansur Shomali, MD, chief medical officer at Welldoc, endocrinologist at MedStar Health
Featuring Mansur Shomali, MD, chief m...
Learn about the state of digital therapeutics for disease management such as diabetes care in terms of cost, outcomes, integration, and more with Dr Mansur Shomali, CMO at Welldoc.
Learn about the state of digital therapeutics for disease management such as diabetes care in terms of cost, outcomes, integration, and more with Dr Mansur Shomali, CMO at Welldoc.
Dr Kevin Cowart, assistant professor at the University of South Florida College of Pharmacy, discusses inclisiran, a new non-statin treatment for high cholesterol.
Dr Kevin Cowart, assistant professor at the University of South Florida College of Pharmacy, discusses inclisiran, a new non-statin treatment for high cholesterol.
In this video, John Hennessey, MBA, Valuate Health Consultancy, explains biosimilars in relation to cancer care: what they are, why they matter, and how they have and haven’t lived up to their promise.
In this video, John Hennessey, MBA, Valuate Health Consultancy, explains biosimilars in relation to cancer care: what they are, why they matter, and how they have and haven’t lived up to their promise.
In this video, Dr Brunner reviews his recent discussion he held at the 2023 AVAHO Annual Meeting, and provides treatment updates in the treatment of MDS.
In this video, Dr Brunner reviews his recent discussion he held at the 2023 AVAHO Annual Meeting, and provides treatment updates in the treatment of MDS.
Featuring Katarina Kesty, MD, MBA, FAAD, Dermatologist and Medical Director at St. Petersburg Skin and Laser
Featuring Katarina Kesty, MD, MBA, FA...
Katarina Kesty, MD, MBA, FAAD, Dermatologist and Medical Director at St. Petersburg Skin and Laser, weighs in on Demodex blepharitis, a condition characterized by inflammation of the eyelid margin caused by an overpopulation of Demodex mites,...
Katarina Kesty, MD, MBA, FAAD, Dermatologist and Medical Director at St. Petersburg Skin and Laser, weighs in on Demodex blepharitis, a condition characterized by inflammation of the eyelid margin caused by an overpopulation of Demodex mites,...